Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemoth...
Clasificación: | Libro Electrónico |
---|---|
Autor principal: | |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Singapore :
Bentham Science Publishers,
2022.
|
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover
- Title
- Copyright
- End User License Agreement
- Contents
- Preface
- List of Contributors
- Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy
- Biswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1
- INTRODUCTION
- CANCER AND ITS TYPES
- Primary Liver Cancer
- Hepatocellular Carcinoma (HCC)
- Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)
- Angiosarcoma and Hemangiosarcoma
- Hepatoblastoma
- Secondary Liver Cancer
- Surgical Resection in Advanced HCC
- Anatomical Resection
- Laparoscopic Resection of The Liver
- Surgical Resection of Re-Occurring HCC
- Liver Transplantation
- Ablation
- Palliative Treatment
- Embolizing Therapies for HCC
- Transarterial Chemoembolization (TACE)
- Radiotherapy
- Systemic Therapies of HCC
- First-line Therapy
- Second-line Therapy
- Multi-Target Tyrosine Kinase Inhibitors
- Immune Checkpoint Inhibitor
- FUTURE PERSPECTIVES
- CONCLUSIONS
- CONSENT FOR PUBLICATION
- CONFLICT OF INTEREST
- ACKNOWLEDGEMENT
- REFERENCES